{"drugs":["Erythrocin Lactobionate","Erythromycin Lactobionate"],"mono":{"0":{"id":"211753-s-0","title":"Generic Names","mono":"Erythromycin Lactobionate"},"1":{"id":"211753-s-1","title":"Dosing and Indications","sub":{"0":{"id":"211753-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Allergy to penicillin - Female gonococcal pelvic inflammatory disease:<\/b> 500 mg IV every 6 hr for 3 days, followed by oral administration of 250 mg erythromycin stearate or base every 6 hr  OR 500 mg erythromycin base ORALLY every 12 hr OR 333 mg erythromycin base ORALLY every 8 hr for 7 days<\/li><li><b>Bartonellosis - HIV infection:<\/b> (bacillary angiomatosis, peliosis hepatis, bacteremia, osteomyelitis) 500 mg IV 4 times daily for at least 3 months<\/li><li><b>Diphtheria, adjunct to antitoxin; Adjunct:<\/b> 15 to 20 mg\/kg\/day IV in divided doses; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Erythrasma:<\/b> 15 to 20 mg\/kg\/day IV in divided doses; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue (Mild to Moderate), Caused by S. pyogenes or S. aureus:<\/b> 15 to 20 mg\/kg\/day IV in divided doses; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Legionnaires disease:<\/b> 1 to 4 g IV daily in divided doses<\/li><li><b>Respiratory tract infection:<\/b> 15 to 20 mg\/kg\/day IV in divided doses (dosing intervals not to exceed every 6 hours); MAX 4 g\/day, depending on type and severity of infection<\/li><\/ul>"},"1":{"id":"211753-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Allergy to penicillin - Female gonococcal pelvic inflammatory disease:<\/b> 500 mg IV every 6 hr for 3 days, followed by oral administration of 250 mg erythromycin stearate or base every 6 hr  OR 500 mg erythromycin base ORALLY every 12 hr OR 333 mg erythromycin base ORALLY every 8 hr for 7 days<\/li><li><b>Bartonellosis - HIV infection:<\/b> (cutaneous bacillary angiomatosis) 15 to 50 mg\/kg\/day (MAX 2 g\/day) IV divided into 4 doses\/day for 3 months<\/li><li><b>Diphtheria, adjunct to antitoxin; Adjunct:<\/b> 15 to 20 mg\/kg\/day IV in divided doses; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Erythrasma:<\/b> 15 to 20 mg\/kg\/day IV in divided doses; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue (Mild to Moderate), Caused by S. pyogenes or S. aureus:<\/b> 15 to 20 mg\/kg\/day IV in divided doses; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Respiratory tract infection:<\/b> 15 to 20 mg\/kg\/day IV in divided doses (dosing intervals not to exceed every 6 hours); MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Respiratory tract infection:<\/b> (community acquired pneumonia; older than 3 months of age) 20 mg\/kg\/day IV divided every 6 hours (guideline dosing)<\/li><\/ul>"},"3":{"id":"211753-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Allergy to penicillin - Female gonococcal pelvic inflammatory disease<\/li><li>Diphtheria, adjunct to antitoxin; Adjunct<\/li><li>Erythrasma<\/li><li>Infection of skin AND\/OR subcutaneous tissue (Mild to Moderate), Caused by S. pyogenes or S. aureus<\/li><li>Legionnaires disease<\/li><li>Respiratory tract infection<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Bartonellosis - HIV infection<\/li><li>Gastroparesis syndrome<\/li><\/ul>"}}},"3":{"id":"211753-s-3","title":"Contraindications\/Warnings","sub":[{"id":"211753-s-3-9","title":"Contraindications","mono":"<ul><li>concomitant use with astemizole or terfenadine<\/li><li>hypersensitivity to erythromycin products<\/li><\/ul>"},{"id":"211753-s-3-10","title":"Precautions","mono":"<ul><li>prolonged QT intervals, cardiac arrest, torsades de pointes and other ventricular arrhythmias have been reported<\/li><li>diarrhea (Clostridium difficile associated), ranging in severity from mild diarrhea to fatal colitis, has been reported; discontinuation may be necessary<\/li><li>elderly patients; increased risk for hearing loss with higher doses, torsades de pointes arrhythmias, increased oral anticoagulant effects<\/li><li> hepatic dysfunction, with or without jaundice, has been reported<\/li><li>hepatic impairment; increased exposure <\/li><li>myasthenia gravis patients; weakness aggravated<\/li><li>superinfection has been reported; discontinue use if suspected<\/li><\/ul>"},{"id":"211753-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Erythromycin: B (FDA)<\/li><li>Erythromycin: A (AUS)<\/li><\/ul>"},{"id":"211753-s-3-12","title":"Breast Feeding","mono":"<ul><li>Erythromycin: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Erythromycin: WHO: Compatible with breastfeeding.<\/li><li>Erythromycin: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"211753-s-4","title":"Drug Interactions","sub":[{"id":"211753-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Astemizole (probable)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (probable)<\/li><li>Colchicine (probable)<\/li><li>Dihydroergotamine (probable)<\/li><li>Dronedarone (theoretical)<\/li><li>Ergoloid Mesylates (probable)<\/li><li>Ergonovine (probable)<\/li><li>Ergotamine (probable)<\/li><li>Fluconazole (theoretical)<\/li><li>Grepafloxacin (probable)<\/li><li>Levomethadyl (probable)<\/li><li>Lomitapide (theoretical)<\/li><li>Lovastatin (probable)<\/li><li>Mesoridazine (established)<\/li><li>Methylergonovine (probable)<\/li><li>Methysergide (probable)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Simvastatin (established)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"211753-s-4-14","title":"Major","mono":"<ul><li>Acecainide (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Ajmaline (probable)<\/li><li>Amiodarone (theoretical)<\/li><li>Amisulpride (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprindine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Atorvastatin (probable)<\/li><li>Azimilide (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Bretylium (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Carbamazepine (established)<\/li><li>Ceritinib (theoretical)<\/li><li>Cerivastatin (probable)<\/li><li>Chloral Hydrate (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clindamycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dibenzepin (theoretical)<\/li><li>Digoxin (established)<\/li><li>Diltiazem (probable)<\/li><li>Disopyramide (probable)<\/li><li>Dofetilide (probable)<\/li><li>Dolasetron (probable)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Encainide (theoretical)<\/li><li>Enflurane (theoretical)<\/li><li>Eplerenone (probable)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Everolimus (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Gatifloxacin (probable)<\/li><li>Gemifloxacin (probable)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (probable)<\/li><li>Haloperidol (theoretical)<\/li><li>Halothane (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Hydroquinidine (probable)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibrutinib (theoretical)<\/li><li>Ibutilide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Isoflurane (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Itraconazole (probable)<\/li><li>Ivabradine (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ketoconazole (probable)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lidoflazine (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lorcainide (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Lurasidone (probable)<\/li><li>Mefloquine (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Naloxegol (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Pirmenol (probable)<\/li><li>Pitavastatin (probable)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Prajmaline (probable)<\/li><li>Primidone (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (probable)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (probable)<\/li><li>Quinine (probable)<\/li><li>Ranolazine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Romidepsin (theoretical)<\/li><li>Sematilide (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (established)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Spiramycin (theoretical)<\/li><li>Sulfamethoxazole (theoretical)<\/li><li>Sultopride (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Tadalafil (theoretical)<\/li><li>Tedisamil (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Theophylline (established)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimethoprim (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Troleandomycin (probable)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vasopressin (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Verapamil (probable)<\/li><li>Vilanterol (theoretical)<\/li><li>Vinblastine (probable)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Warfarin (established)<\/li><li>Zolmitriptan (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},{"id":"211753-s-4-15","title":"Moderate","mono":"<ul><li>Alfentanil (probable)<\/li><li>Alprazolam (probable)<\/li><li>Anisindione (probable)<\/li><li>Avanafil (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bromocriptine (probable)<\/li><li>Budesonide (probable)<\/li><li>Buspirone (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Diazepam (probable)<\/li><li>Dicumarol (probable)<\/li><li>Methylprednisolone (probable)<\/li><li>Midazolam (established)<\/li><li>Phenprocoumon (probable)<\/li><li>Roflumilast (established)<\/li><li>Salmeterol (established)<\/li><li>Sildenafil (probable)<\/li><li>Sirolimus (probable)<\/li><li>Tolterodine (probable)<\/li><li>Triazolam (probable)<\/li><li>Trimetrexate (probable)<\/li><li>Valproic Acid (probable)<\/li><li>Zafirlukast (probable)<\/li><\/ul>"}]},"5":{"id":"211753-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Irritation symptom, Venous (occasional)<\/li><li><b>Dermatologic:<\/b>Urticaria<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Prolonged QT interval (rare), Ventricular tachycardia (rare)<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis (rare)<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Otic:<\/b>Hearing loss, Patients with renal insufficiency (high doses)<\/li><\/ul>"},"6":{"id":"211753-s-6","title":"Drug Name Info","sub":{"0":{"id":"211753-s-6-17","title":"US Trade Names","mono":"Erythrocin Lactobionate<br\/>"},"2":{"id":"211753-s-6-19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Macrolide<\/li><\/ul>"},"3":{"id":"211753-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"211753-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"211753-s-7","title":"Mechanism Of Action","mono":"Erythromycin lactobionate is a macrolide antibiotic acts by binding to 50 S ribosomal subunits of susceptible pathogens.<br\/>"},"8":{"id":"211753-s-8","title":"Pharmacokinetics","sub":{"2":{"id":"211753-s-8-25","title":"Metabolism","mono":"Hepatic <br\/>"},"3":{"id":"211753-s-8-26","title":"Excretion","mono":"<ul><li>Biliary<\/li><li>Renal: 12% to 15% unchanged<\/li><li>Dialyzable: no (hemodialysis); no (peritoneal dialysis)<\/li><\/ul>"}}},"9":{"id":"211753-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for IV use only<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>(vials) reconstitute only with Sterile Water for Injection, USP to a concentration of 50 mg\/mL; do not use diluents containing preservatives or inorganic salts<\/li><li>(continuous infusion) dilute the reconstituted solution with NS or LR to a concentration of 1 mg\/mL and use within 8 hours<\/li><li>(intermittent infusion) dilute the reconstituted solution with no less than 100 mL of NS or LR to a concentration of 1 to 5 mg\/mL and infuse over 20 to 60 minutes at intervals not greater than every 6 hours; use within 8 hours of preparation<\/li><li>(infusion) may also dilute reconstituted solution with D5W, D5WLR, or D5NS provided they are buffered by addition of 1 mL of Neut(R) (4% sodium bicarbonate) per 100 mL of solution<\/li><li>continuous (preferable) or intermittent IV infusion only; do not use IV push<\/li><li>(ADD-vantage vials) add the 500 mg vial to 100 mL of NS or D5W in the ADD-vantage flexible diluent container for a concentration of 5 mg\/mL and use within 8 hours of preparation<\/li><li>(ADD-vantage vials) add the 1 g vial to 250 mL of NS or D5W in the ADD-vantage flexible diluent container for a concentration of 4 mg\/mL and use within 2 hours of preparation<\/li><\/ul><\/li><\/ul>"},"10":{"id":"211753-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement<\/li><li>hepatic function<\/li><li>hearing exam (hearing loss, especially with high doses and renal or hepatic insufficiency)<\/li><\/ul>"},"11":{"id":"211753-s-11","title":"How Supplied","mono":"<b>Erythrocin Lactobionate<\/b><br\/>Intravenous Powder for Solution: 1 GM, 500 MG<br\/>"},"12":{"id":"211753-s-12","title":"Toxicology","sub":[{"id":"211753-s-12-31","title":"Clinical Effects","mono":"<b>MACROLIDE ANTIBIOTICS <\/b><br\/>OVERDOSE: Significant toxicity following acute overdose is uncommon.  N\/V, abdominal pain may occur.  ADVERSE EFFECTS: N\/V, abdominal pain, diarrhea most common.  Cholestasis, sensorineural hearing loss, thrombophlebitis (IV administration), ventricular dysrhythmias\/QT prolongation (IV administration) are less common. <br\/>"},{"id":"211753-s-12-32","title":"Treatment","mono":"<b>MACROLIDE ANTIBIOTICS <\/b><br\/><ul><li>Decontamination: Activated charcoal, gastric lavage.<\/li><li>Support: Therapy as indicated.<\/li><li>Abdominal discomfort: Food, milk or an antacid  may be given; most effects reverse with drug cessation<\/li><li>Monitoring of patient: Baseline ECG, cardiac monitoring as indicated. Renal and hepatic function as indicated.<\/li><\/ul>"},{"id":"211753-s-12-33","title":"Range of Toxicity","mono":"<b>MACROLIDE ANTIBIOTICS<\/b><br\/>In general, the macrolide antibiotics are of a low order toxicity. <br\/>"}]},"13":{"id":"211753-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patients to report signs\/symptoms ototoxicity, especially elderly patients on high-dose regimens or with renal insufficiency.<\/li><li>Patients with a history of myasthenia gravis should report signs\/symptoms of disease exacerbation during therapy.<\/li><li>Patient should avoid concomitant use of terfenadine or astemizole.<\/li><\/ul>"}}}